KabaFusion LLC
12/24/2025 | Press release | Archived content
Efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy, with or without diabetes: insights from a multicenter prospective[...]
Efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy, with or without diabetes: insights from a multicenter prospective comparative study
A multicenter prospective comparative study was recently published in Therapeutic Advances in Neurological Disorders. The publication characterizes the efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy, with or without diabetes.
This study was authored by Samir P. Macwan, Shalini Mahajan, Peter Novak, Khosro Farhad, Ericka Wong, Thomas H. Brannagan, Sohail Masood, Fawad Piracha and Marinos C. Dalakas.
View the article here: https://doi.org/10.1177/17562864251401496
KabaFusion LLC published this content on December 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 21, 2026 at 07:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]